Phase I clinicals of the company's targeted liposomal daunorubicin to begin soon. The trial will involve patients with metastatic tumors. Vestar intends the Phase II portion of the study to focus on treating tumors of various types, particularly Kaposi's sarcoma. Vestar in collaboration with LyphoMed has another liposomal cancer drug in clinicals. A Phase II trial of liposomal doxorubicin is ongoing at Georgetown University. Under the 50/50 R&D venture, Vestar retains manufacturing rights and LyphoMed handles marketing and sales.
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”